Nanotherapeutics Advances Two Clinical Programs
Business Wire - March 2009
Nanotherapeutics, Inc. has submitted an Investigational New Drug (IND) application to the FDA for a Phase I clinical studies to assess the safety and pharmacokinetics of NanoBUP™ buprenorphine/naloxone capsule for the treatment of opiate addiction. NanoBUP™ is a stable, oral swallowed capsule containing buprenorphine/naloxone developed with the company?s proprietary NanoDRY® particle delivery system. This new product is an immediate release capsule that allows buprenorphine to be absorbed more efficiently from the upper gastrointestinal tract upon ingestion, offering a less invasive route of administration and potentially reducing patient-to-patient variability.